Bright future or blind alley? CAR-T cell therapy for solid tumors

Chimeric antigen receptor (CAR) T cells therapy has emerged as a significant breakthrough in adoptive immunotherapy for hematological malignancies with FDA approval. However, the application of CAR-T cell therapy in solid tumors remains challenging, mostly due to lack of suitable CAR-T target antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kai, Chen, Hong, Li, Fuqiang, Huang, Sheng, Chen, Fei, Li, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902507/
https://www.ncbi.nlm.nih.gov/pubmed/36761757
http://dx.doi.org/10.3389/fimmu.2023.1045024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902507/
https://www.ncbi.nlm.nih.gov/pubmed/36761757
http://dx.doi.org/10.3389/fimmu.2023.1045024

Ejemplares similares